Collegium Pharmaceutical, Inc.

Quick facts

Phase 3 pipeline

• Oxycodone DETERx · Pain Management
  Oxycodone DETERx is an extended-release formulation of oxycodone, a mu-opioid receptor agonist, designed with abuse-deterrent technology to reduce the potential for misuse.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Collegium Pharmaceutical, Inc. portfolio CI brief
• Collegium Pharmaceutical, Inc. pipeline updates RSS